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Lack of patient tissue and relevant diseasemodels have constrained progress toward discovering the causes
of schizophrenia. Recently in Nature, Brennand et al. (2011) reprogram schizophrenia patient fibroblasts to
derive four iPSC lines, perform subsequent neural differentiation, and provide early insights into a novel
approach that may address these issues.Schizophrenia has a prevalence of
approximately 1% worldwide, and is
characterized by hallucinations, delu-
sions, and cognitive deficits, with
heritability estimated at up to 80%
(Owen et al., 2010). The only readily avail-
able human schizophrenia brain tissue
comes from postmortem samples and is
subject to numerous, difficult-to-control
potential artifacts, including abnormal
brain pH influenced by hypoxia near
death, lengthy postmortem interval,
patient drug and alcohol use, and medi-
cation treatment (Deep-Soboslay et al.,
2011). Despite these challenges, several
abnormalities have been reported,
including changes in specific neurotrans-
mitter systems (Dean et al., 2009).
However, these observations implicate
many neural systems, and it has not
been possible, thus far, to convincingly
determine whether the specific changes
are primary or secondary effects of the
disease process.
Schizophrenia is often referred to as
a neurodevelopmental disorder (Insel,
2010). While overt clinical symptoms
usually have their onset in late adoles-
cence or early adulthood, disturbed
cognitive functions are being increasingly
reported at substantially earlier times,
implying that it will be important to study
the early phases of neural development
and differentiation long before the onset
of the disease (Koenen et al., 2009).
Recent genetic studies have demon-
strated a highly complex landscape in
schizophrenia (Owen et al., 2010). For
example, rare specific copy number vari-
ants have been shown to increase schizo-
phrenia risk as much as 20-fold, and, ingeneral, schizophrenia patients have an
increased rate of copy number variants,
including those that are inherited and
that arise de novo (Sebat et al., 2009). In
addition to copy number changes, recent
genome-wide association studies have
identified statistically compelling, repli-
cated common-DNA variants in several
genes, as well as a large polygenic set of
effects (Purcell et al., 2009; Insel, 2010).
Existing animal model strategies are
inadequate to deal with this level of
complexity.
In their recent study published in
Nature, Brennand et al. (2011) offer hope
that significant advances on the fronts
noted above may soon be possible, by
generating the first reported induced
pluripotent stem cell (iPSC) lines from
schizophrenia patients, or indeed from
any complex psychiatric condition (Bren-
nand et al., 2011). They selected fibro-
blasts from four patients from three
families for five-factor (OCT4, SOX2,
KLF4, cMYC, LIN28)-mediated reprog-
ramming using now ‘‘standard’’ doxycy-
cline-inducible lentiviral vectors. Basic
experiments, including teratoma assays,
demonstrated the pluripotency of the
cell lines created, and the resulting iPSC
lines were induced to form neural cells
(primarily glutamatergic and GABAergic
neurons) using a cocktail of factors and
coculture with cerebellar astrocytes. The
authors utilized a large battery of tests to
explore key aspects of neural functioning
relative to iPSC lines derived from age-
and ancestry-matched normal donors,
including assays of neuronal connectivity,
neurite outgrowth, synaptic protein
expression, synaptic density, electro-Cell Stem Cphysiology, spontaneous calcium tran-
sient imaging, and gene expression.
Basic neuronal properties, measured
with electrophysiology and calcium
imaging, were normal in the patient-
derived iPSCs. In contrast, neuronal
connectivity, measured by assessing the
transneuronal transport of a modified
rabies virus, was decreased in the schizo-
phrenia-derived iPSCs. While the mecha-
nism behind this defect remains to be
elucidated, it might be due to decreased
synaptic density, reflected in reduced
levels of synaptic proteins and a trend
toward reduced PSD95 synaptic density.
Reduced synaptic density could in turn
be caused by the observed decrease in
the number of neurites in these cultures.
While the sample size remains too low to
support general conclusions about
a heterogeneous disorder like schizo-
phrenia, this study highlights that the use
of living neurons from affected individuals
will likely permit the eventual identification
of the mechanisms behind the neural
abnormalities described in schizophrenia.
Gene-expression profiling was carried
out in the iPSCs, and close to 600 genes
were differentially regulated in the schizo-
phrenia samples. The authors note that
expression of the NRG1 gene, which
may be altered in schizophrenia, was
elevated in iPSC-derived neurons, but
not in patient fibroblasts, highlighting
the importance of studying relevant cell
types. In addition, the authors were
able to test five antipsychotic drugs for
their ability to reverse the observed
deficits in neuronal connectivity, and
showed that loxapine was effective in
this assay. Loxapine also reversed someell 8, May 6, 2011 ª2011 Elsevier Inc. 461
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Previewsof the gene-expression changes in the
patient-derived iPSCs, including reducing
expression of the schizophrenia risk gene
TCF4 to normal levels. Again, the avail-
ability of living neurons permitted these
examinations. The ability to differentiate
iPSCs into diverse cell types, including
oligodendrocytes, which have previously
been implicated in schizophrenia (Taka-
hashi et al., 2011), will permit a broad
look at cellular alterations that take place
in psychiatric and neurological diseases.
We can now look forward to amuch better
understanding of the relationship between
genetic risk factors, gene-expression
changes, and neuronal and glial function
in schizophrenia, as well as opportunities
to perform high-throughput screening of
compound libraries in patient-derived
neuronal and glial cells as a step toward
relevant drug discovery.
While this effort from Brennand et al.
(2011) is just a beginning, the now wide-
spread availability of fibroblasts (andother462 Cell Stem Cell 8, May 6, 2011 ª2011 Elscells) from patients with schizophrenia
andother complexdisorderswill undoubt-
edly lead to very large-scale studies using
assays such as those employed by Bren-
nand et al. (2011). The authors suggest
that with the examination of an increasing
number of patient-derived lines, the list of
consistently affected genes will be dimin-
ished. In our opinion, the addition of future
studies will likely lead to subgrouping of
iPSCs, based on the patterns of pathways
that are impacted in each case. In disor-
ders such as schizophrenia with high
heritability, determining the relationship
between the genetic variations present in
the iPSCs that cluster to each of these
subgroups will then permit the prospec-
tive assignment of individual patients to
a given subgroup, based solely on results
of DNA sampling. The opportunity to iden-
tify interventions that are most effective in
specific subgroups represents the ulti-
mate promise of individualized medicine
in complex disease.evier Inc.REFERENCES
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Epithelial plasticity is crucial during embryonic development and progression of carcinomas. In this issue,
Abell et al. (2011) show that acetylation on histones H2A/H2B prevents epithelial cells from undergoing
epithelial-to-mesenchymal transition (EMT). Their findings also suggest that under conditions where EMT
and stemness coexist, they can be independently regulated.Epithelial plasticity is the biologicalmecha-
nism underlying organ formation. During
embryonic development, many tissues
and organs originate after one or several
rounds of EMT and the reverse process,
mesenchymal-to-epithelial transition, or
MET. In adulthood, epithelial homeostasis
is instead important to maintain tissue
architecture, and reactivation of the EMT
program is associated with progression of
carcinomas and organ fibrosis (Thiery
et al., 2009). Recent work suggests that
cancer progression and reactivation ofdevelopmental programs such as EMT
are both associated with acquisition of
stem cell properties. Indeed, poorly differ-
entiated and invasive human tumors in
addition to expressing EMT markers
also show an embryonic stem cell (ESC)
signature (Ben-Porathetal., 2008).Further-
more, inducing EMT inmammary epithelial
cells by overexpressing transcription
factors Snail or Twist has been shown to
confer stem cell properties (Mani et al.,
2008). However, the reverse process,
MET, has also been reported to be animportant component, driving reprogram-
ming of fibroblasts to induced pluripotent
stem cells (iPSCs) (Li et al., 2010; Sama-
varchi-Tehrani et al., 2010), findings which
suggest that the interrelationship between
stem cell properties and EMT or MET is
complex. In this issue of Cell Stem Cell,
Abell et al. (2011) use trophoblast stem
(TS) cells as a model system to confirm
that stem cell properties and EMT signa-
tures coexist in a developmental context
as well as in cancer cells. They also report
that histone 2A/2B acetylation represents
